These findings are of interest, as a number of Xarelto lawsuits have been filed that question claims made by the drug’s manufacturers regarding the purported superiority of Xarelto over warfarin.
New York, New York (PRWEB) December 13, 2014
As Xarelto lawsuits (http://www.xareltolawsuit2015.com/) continue to mount in U.S. court, Bernstein Liebhard LLP notes the publication of a study that suggests the new blood thinner is no safer than warfarin, a medication that has been on the market for decades. The research, which was published this month in the Canadian Journal of Cardiology, looked at 901 patients who underwent cardioversion and were given either warfarin, or a new-generation blood thinner, including rivaroxaban, which is currently sold under the brand name Xarelto. The authors of the study observed that all of the medications were associated with similar rates of internal bleeding and other complications.*
“These findings are of interest, as a number of Xarelto lawsuits have been filed that question claims made by the drug’s manufacturers regarding the purported superiority of Xarelto over warfarin,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free, no-obligation Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto Lawsuit Allegations
Xarelto (rivaroxaban) was approved by the U.S. Food & Drug Administration in 2011, and is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery. **
Court documents indicate at least 50 Xarelto lawsuits are now pending in U.S. courts, all of which were filed on behalf of individuals who allegedly suffered uncontrollable bleeding and other serious complications due to its use. The U.S. Judicial Panel on Multidistrict Litigation is currently considering a petition to consolidate all federally-filed claims before a single judge for coordinated pretrial proceedings. The Panel heard Oral Argument on the matter on December 4th, but has yet to render a decision. (In Re: Xarelto Products Liability Litigation, No. 2592)
All of the Xarelto lawsuits similarly allege that the drug’s manufacturers wrongly marketed it as a superior alternative to warfarin, a blood thinner that has been in use for decades. The complaints point out that while there is currently no approved antidote to reverse Xarelto bleeding, hemorrhaging associated with warfarin can be stopped via the administration of Vitamin K.
Individuals who were allegedly harmed by Xarelto may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.
*onlinecjc.ca/article/S0828-282X%2814%2901402-0/abstract, Canadian Journal of Cardiology, December 2014
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP